Business Wire India

India’s leading natural pet wellness brand, Dogsee Chew, made a landmark debut at the 79th edition of the Cannes Film Festival on May 16, 2026, becoming one of the first Indian pet wellness brands to represent the industry on one of the world’s most prestigious global platforms.

 

Representing the brand at Cannes were co-founders and pet parents Sneh Sharma and Bhupendra Khanal, whose powerful red carpet appearance highlighted the growing cultural and global significance of pet wellness. As pets increasingly become integral members of families worldwide, conversations around natural nutrition, preventive care, wellness, and mindful pet parenting are rapidly entering mainstream lifestyle and consumer spaces.

 

Founded in 2015, Dogsee Chew pioneered the Himalayan yak chew category globally with its natural Chhurpi-based dog treats sourced from the Himalayas. Today, the Bengaluru-based company is present in over 30 countries and trusted by more than a million pet parents worldwide for its preservative-free, rawhide-free, and natural pet nutrition offerings.

 

What made the Cannes appearance especially emotional was the founders’ heartfelt tribute to their late dog, Mowgli — the inspiration behind Dogsee Chew’s journey. The theme of their red carpet appearance, titled “An Ode To Mowgli,” beautifully blended emotion, fashion, and Himalayan heritage.

 

Sneh Sharma wore a custom ensemble by Indian label Duchess Kumari, paired with jewellery from Kushal Fashion Jewellery. Her outfit featured intricate Himalayan-inspired detailing along the hem symbolising the brand’s roots, while the corset carried an embroidered motif of Mowgli. Bhupendra Khanal wore a custom suit by Twamev featuring Mowgli’s embroidered motif on the left chest — a subtle yet deeply emotional tribute to the dog who inspired the company’s vision.

 

Speaking about the moment, Sneh Sharma, Co-founder, Dogsee Chew, said, “Walking the Cannes red carpet was an incredibly emotional and proud moment for us. Mowgli was not just our pet, but the soul behind Dogsee’s journey. Through this tribute, we wanted to celebrate the unconditional love pets bring into our lives while also representing India, the Himalayas, and the growing global conversation around pet wellness on such an iconic platform.”

 

Bhupendra Khanal, Co-founder, Dogsee Chew, added, “For us, Cannes is much bigger than a red carpet moment. It represents how far the pet wellness industry has evolved globally. Seeing a Himalayan-born Indian brand being recognised on an international stage reinforces the growing importance of conscious pet parenting, natural nutrition, and wellness-led lifestyles worldwide. Carrying Mowgli’s memory with us made this moment deeply personal and unforgettable.”

 

Dogsee Chew’s presence at Cannes also reflects the larger transformation taking place within the global pet care industry. Once considered a niche segment, pet wellness has rapidly emerged as one of the world’s fastest-growing consumer categories, driven by increasing awareness around animal health, preventive care, and premium nutrition.

 

Over the years, Dogsee Chew has expanded its portfolio beyond Himalayan Yak Chews into dental chews, training treats, puffed snacks, functional variants, and wellness supplements under its Dogsee Activet Plus+ range. As the company continues to strengthen its presence across India, the US, Canada, Europe, and the Asia-Pacific region, Dogsee Chew aims to position Himalayan natural nutrition as a global benchmark in pet wellness while building one of the world’s most trusted pet care brands from India.

 

YouTube Link: https://www.youtube.com/shorts/H7C0FbMm7P0

Business Wire India

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy

 

BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL

 

Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise

 

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA^® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI^™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL.

 

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said:
“CLL is a disease patients live with for years, and the real measure of a therapy is how it performs over the long arc of treatment. Our data at ASCO show that BRUKINSA continues to deliver sustained disease control, which can give physicians and patients confidence to stay the course. Additionally, robust, real-world analyses reinforce its role as a best-in-class BTK inhibitor, with data favoring BRUKINSA over other BTK inhibitors across several efficacy and safety endpoints. With BRUKINSA as the foundation, we are building a broad, differentiated hematology franchise designed to push the field further, including our ZS combination, which achieved deep responses and unprecedented rates of uMRD, and emerging approaches like our BTK degrader, tacabrutideg. Together, these foundational therapies reflect our commitment to redefining what patients should expect from therapy both today and in the future.”

 

 

78-month SEQUOIA data highlight the long-term impact of first-line treatment choice in CLL (Poster Presentation: 544; June 1, 2026, 9:00 AM-12:00 PM CDT)
SEQUOIA now provides the longest reported follow-up for a next-generation BTK inhibitor in first-line CLL, enabling a deeper understanding of how treatment outcomes evolve over time. After a median follow-up of 84.01 months (range, 0.0-101.5), BRUKINSA continued to show benefit over bendamustine-rituximab (BR) in patients with treatment-naive CLL/SLL, with progression-free survival (PFS) outcomes that are unprecedented among BTK inhibitors. Key highlights include:

 

 

• 78-month PFS: 71.8% (95% CI, 65.3-77.3) for BRUKINSA vs. 31.0% (95% CI, 24.3-37.9) for BR
• 78-month COVID-adjusted PFS: 74.6% (95% CI, 68.1-79.9) for BRUKINSA vs. 31.4% (95% CI, 24.7-38.4) for BR
  • PFS for patients with unmutated IGHV: 70.4% (95% CI, 61.0-77.9) for BRUKINSA vs. 17.4% (95% CI, 9.6-27.1) for BR
  • PFS for patients with mutated IGHV: 81.8% (95% CI: 72.2-88.4) for BRUKINSA and 45.1% (95% CI: 34.4-55.2) for BR
• 78-month PFS2: 81.3% (95% CI, 75.6-85.8) for BRUKINSA vs. 74.4% (95% CI, 67.8-79.8) for BR
• 78-month COVID-adjusted PFS2: 84.7% (95% CI, 79.2-88.8) for BRUKINSA and 76.4% (95% CI, 69.9-81.7) for BR
  • Of the BRUKINSA-treated patients who progressed (26/241), half received subsequent therapy with BCL2 inhibitor-based salvage therapy and 69.2% had not progressed after more than 3 years of follow-up.
• Time to next treatment (TTNT) favored BRUKINSA over BR (HR, 0.24; 95% CI, 0.16-0.35; P<.0001)
• Safety: consistent with the results of prior BRUKINSA studies with no new safety signals.

 

 

PFS2 captures outcomes beyond first disease progression, measuring time to disease progression on subsequent therapy or death. In CLL, this endpoint provides important insight into how first-line treatment impacts long-term disease control across multiple lines of therapy.

 

Constantine Tam, M.B.B.S., M.D., Head of Lymphoma Service at Alfred Health and Professor of Haematology at Monash University, said:
“In an indolent disease like CLL, many patients value maintaining disease control over the course of their life, not just in the first year or two of treatment. The continued long-term follow-up from SEQUOIA shows that zanubrutinib can deliver sustained disease control. This is the kind of evidence that allows clinicians and patients to make first-line decisions with real confidence about what lies ahead.”

 

 

Real-world efficacy and safety data consistently underscore foundational BRUKINSA as the best-in-class BTKi for TN CLL (Poster Presentations: 545, 543 and 540; June 1, 2026, 9:00 AM-12:00 PM CDT)
In addition to the update from SEQUOIA, BeOne will present data from new analyses of large and robust datasets, which demonstrate consistent and significant real-world benefits of using BRUKINSA over other BTK inhibitors. Key highlights include:

 

 

• In a real-world analysis of 10,523 Medicare patients, who were diagnosed with CLL/SLL and received frontline treatment with a BTK inhibitor, patients treated with BRUKINSA had a statistically significantly lower risk of death, advancing to next line, or discontinuing treatment, than those on ibrutinib or acalabrutinib. Similar results were observed across age subgroups. (Poster Presentation: 545)
• In a separate real-world analysis of Komodo database claims from 16,788 patients with treatment-naïve CLL, BRUKINSA had a longer TTNT (unadjusted HR, 0.88; 95% CI, 0.79-0.97; P=.009) and overall survival (OS; HR, 0.72; 95% CI, 0.62-0.82; P<.001). (Poster Presentation: 543)
• A retrospective analysis of 233,362 newly diagnosed CLL patients who initiated treatment with a BTK inhibitor, the atrial fibrillation rate within 1 year was lowest for BRUKINSA at 11% and 13% for acalabrutinib and 16% for ibrutinib (overall P<.0001). (Poster Presentation: 540)

 

 

Deep, rapid responses with BRUKINSA plus sonrotoclax (ZS) point to the future of time-limited treatment in CLL, including high-risk disease (Poster Presentation: 541; June 1, 2026, 9:00 AM-12:00 PM CDT)
In the Phase 1/1b study in patients with treatment-naïve CLL/SLL (median follow-up of ~34 months), the all-oral combination of BRUKINSA and next-generation BCL2 inhibitor sonrotoclax (ZS) demonstrated unprecedented rates and kinetics of undetectable minimal residual disease (uMRD), including in patients with high-risk cytogenetics. Key highlights include:

 

• Overall response rate (ORR): 100%, with complete responses in 59.5% of patients
• Best uMRD4 rate 98.8%
  • No patient that achieved uMRD4 reverted to uMRD positivity.
• Best uMRD in patients with TP53 mutation/del(17p): 92.9% across 2 dose levels
• Median time from combination start to uMRD4: 4.5 months
• No disease progression events observed at the recommended Phase 2 dose of 320mg, including patients who electively discontinued therapy
• Safety: consistent with previously reported BRUKINSA and sonrotoclax combination studies.

 

 

These data will also be presented as encore presentations at the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm) along with more than 30 other data sets from BeOne.

 

About BRUKINSA^® (zanubrutinib)
BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

 

 

With the broadest label globally, BRUKINSA is the foundational BTK inhibitor and is the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study. It is also the only BTK inhibitor to provide the flexibility of once or twice daily dosing.

 

 

The global BRUKINSA clinical development program includes more than 8,000 patients enrolled in over 30 countries and regions across more than 45 trials. BRUKINSA is approved in 80 markets in at least one indication, and more than 290,000 patients have been treated globally.

 

 

About BEQALZI^™ (sonrotoclax)
BEQALZI^™ (sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. Sonrotoclax has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,500 patients have been enrolled across the broad sonrotoclax global development program.

 

 

BEQALZI is approved by the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a BTK inhibitor. It is also approved in China for adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy, including a BTK inhibitor.

 

 

About Tacabrutideg (BGB-16673)
Tacabrutideg is a foundational and potential first-in-class and best-in-class orally available Bruton’s tyrosine kinase (BTK) degrader. With 1,200+ patients dosed to date in an extensive global clinical development program, tacabrutideg is the most advanced BTK degrader in the clinic. This program includes three randomized Phase 3 trials in R/R CLL, including the head-to-head Phase 3 trial versus pirtobrutinib, which began enrolling in Q4 2025. Originating from BeOne’s chimeric degradation activation compound (CDAC) platform, tacabrutideg is designed to promote the degradation, or breakdown, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease.

 

 

The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to tacabrutideg for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Additionally, the European Medicines Agency (EMA) granted tacabrutideg PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom’s macroglobulinemia (WM) previously treated with a BTK inhibitor.

 

 

Select Important Safety Information for BRUKINSA
Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity (including drug-induced liver injury).

 

 

In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

 

 

Please see full U.S. Prescribing Information including U.S. Patient Information.

 

 

Select Important Safety Information for BEQALZI^™ (sonrotoclax)
Serious and sometimes fatal adverse reactions have occurred with BEQALZI, including tumor lysis syndrome (TLS), serious infections, neutropenia, and embryo-fetal toxicity. BEQALZI is contraindicated with strong CYP3A inhibitors at initiation and during the ramp-up phase due to the potential for an increased risk of tumor lysis syndrome.

 

 

In the safety population (N=115), tumor lysis syndrome occurred in 7% of patients who followed the recommended dose ramp-up. Serious infections occurred in 14% of patients, and Grade 3 or 4 infections occurred in 17% (fatal: 2.6%), with pneumonia (10%) being the most common Grade 3 or greater infection. Grade 3 or 4 decreases in neutrophils occurred in 18% of patients (Grade 4: 6%), and febrile neutropenia occurred in 1.7% of all patients. The most common adverse reactions (≥15%) were pneumonia (16%) and fatigue (16%). The most common Grade 3–4 laboratory abnormalities (≥15%) were decreases in lymphocytes (29%) and neutrophils (18%).

 

 

Please see full Prescribing Information.

 

 

The information provided in this press release is intended for a global audience. Product indications vary by region.

 

 

About BeOne
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

 

 

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential patient benefits of zanubrutinib, sonrotoclax and tacabrutideg; BeOne’s ability to redefine what patients should expect from therapy; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

 

 

To access BeOne media resources, please visit our Newsroom.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529392296/en/

 

Business Wire India

Charoen Pokphand Foods Public Company Limited (CPF) and FPT Corporation (FPT) recently signed a Memorandum of Understanding (MoU) for a strategic cooperation in Vietnam between CPF and FPT to advance AI-led and digital transformation in agri-food value chains, with the focus on agriculture, food processing, smart manufacturing, and supply chain management in Vietnam.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529529814/en/

 

 

 

The MoU exchange ceremony took place at the Thailand-Vietnam Business Forum 2026, held on May 28, 2026, in Bangkok. The event was attended by the Prime Minister of the Kingdom of Thailand, H.E. Anutin Charnvirakul, and the Vietnam Party General Secretary and State President, H.E. To Lam, commemorating the 50th Anniversary of Vietnam–Thailand Diplomatic Relations (1976–2026) under the theme “Growing Together,” highlighting Vietnam’s strategic commitment to technology-driven growth.

 

Under the agreement, C.P. Vietnam Corporation (C.P. Vietnam), a subsidiary under CPF and Vietnam’s leading integrated agri-food corporation, and FPT will explore the development and deployment of AI and digital solutions across C.P. Vietnam’s integrated Feed-Farm-Food value chain, from farm to family, and supply chain networks, from 2026 to 2028 and beyond.

 

 

The scope of cooperation covers strategic areas including Smart Camera and AI Vision, Smart Scales and Customer Experience, Smart Manufacturing and Smart Supply Chain, Industrial Internet of Things (IIoT) platforms, Centralized Data Integration, Agentic AI for Operational Intelligence, Food Safety and Traceability, and Smart Farm Model and Farmer Ecosystem Expansion.

 

 

In the pilot phase, both sides will establish Smart Farm models at selected C.P. Vietnam facilities, targeting about 20% reduction in operational costs and 100% food safety traceability. The ambition is to turn the Smart Farm model into a practical engine for wider transformation, bringing FPT’s AI solutions into more C.P. Vietnam facilities and across its contract farmer network. This can create a pathway for Smart Farm and AI AgriTech solutions to reach farmers nationwide, supporting Vietnam’s broader agricultural modernization agenda.

 

 

“With our AI-first strategy and proven capabilities in supporting global manufacturers, FPT will cooperate with C.P. to build a smarter, more connected, and resilient agri-food ecosystem, moving towards AI-enabled smart agriculture while adding value to all of its stakeholders. This partnership reflects a broader opportunity for Vietnam and Thailand to harness next-generation technologies to drive regional impact, strengthen food security, and sustain the growth and competitiveness of Southeast Asia’s agricultural value chains,” said Levi Nguyen, Chief Executive Officer of FPT Thailand and FPT Taiwan, FPT Corporation.

 

 

“C.P. Vietnam supports the Vietnam–Thailand Comprehensive Strategic Partnership Action Program 2026–2030, which promotes economic cooperation, investment, technology transfer, and digital transformation. Through this cooperation with FPT, we look forward to leveraging digital transformation across C.P. Vietnam’s integrated Feed–Farm–Food value chain, from farm to family. C.P. Vietnam continues its efforts to become a trusted partner in shaping the sustainable future of Vietnam’s agri-food industry and nurturing life by delivering safe, high-quality offerings through innovative and sustainable practices,” said Pawalit Ua-amornwanit, Chief Executive Officer of C.P. Vietnam.

 

 

Since its establishment, FPT has become a trusted technology partner for more than 500 enterprises in the Asia Pacific, helping enterprises modernize complex operations and accelerate digital transformation at scale. With Thailand among the key regional markets, the company serves leading enterprises across banking and finance, insurance, retail, automotive, manufacturing, healthcare, energy and utilities, consumer goods, and aviation, with clients and partners including Unilever, Central Group, AIA, LMG, Prudential, KBTG, SCB, KKP, TTB, FWD, Honda, Panasonic, Mitsubishi, Hitachi, Microsoft and Sunline. As a co-founder of the Vietnam–Thailand Chamber of Commerce (VietCham Thailand), the company also plays an active role in strengthening bilateral cooperation.

 

 

About FPT

 

 

FPT Corporation (FPT) is a globally leading Vietnam-headquartered technology and IT services provider, with operations spanning more than 30 countries and territories. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. With a strong focus on mastering strategic technologies, FPT continues to drive innovation across industries. As an AI-first company, FPT is committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises. In 2025, FPT reported a total revenue of USD 2.66 billion and a workforce of over 54,000 employees across its core businesses.
For more information about FPT’s global IT services, please visit https://fptsoftware.com.

 

 

About C.P. Vietnam Corporation

 

 

C.P. Vietnam Corporation, a member of Charoen Pokphand Group, has been operating in Vietnam since 1993. Today, C.P. Vietnam is one of the leading agri-food corporations in Vietnam, operating an integrated Feed – Farm – Food business model in accordance with international standards to deliver high-quality and sustainable food solutions from farm to family.

 

 

Sustainability is embedded at the core of C.P. Vietnam’s business strategy and is driven through three key commitments: climate protection, improving quality of life, and advancing sustainable food systems. C.P. Vietnam is working toward its goal of achieving net-zero emissions by 2050, while continuing to expand renewable energy adoption and strengthen responsible resource management across its operations.

 

 

C.P. Vietnam currently operates 12 animal feed mills, 2 pork slaughterhouses, and 6 food processing plants, including one of Southeast Asia’s most advanced integrated chicken processing complex for export, alongside a nationwide network of modern farms across multiple provinces and cities.

 

 

Throughout more than three decades of operations in Vietnam, C.P. Vietnam has remained steadfast in its “Three Benefits Principle”, placing the benefits of the country and its people at the center of its values. C.P. Vietnam continuously strives to be the trusted partner in shaping the sustainable future of agri-food industry.

 

 

For more information about C.P. Vietnam, please visit https://www.cp.com.vn

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529529814/en/